ELITISM: Epidemic Profile of Left Ventricular Diastoic Dysfunction in the Community Elderly and Establishing Prediction Model: the Northern Shanghai Study

Sponsor
Ya-Wei Xu (Other)
Overall Status
Completed
CT.gov ID
NCT03735251
Collaborator
(none)
1,920
1

Study Details

Study Description

Brief Summary

This study is one of the largest ongoing prospective population studies to evaluate target organ damages (TODs) and Left Ventricular Diastoic Dysfunction in the community-dwelling elderly Chinese, which is authorised and funded by the Shanghai municipal government.This study was approved by the Shanghai Tenth People's Hospital Institutional Review Board and was conducted under financial support from the Shanghai municipal government (grant ID: 2013ZYJB0902 and 15GWZK1002). The preliminary sample size is expected to be 3000-4000 participants.

Condition or Disease Intervention/Treatment Phase
  • Other: Diuretic,Betaloc,antiplatelet drugs

Detailed Description

The Northern Shanghai Study is an ongoing prospective community-based study. After enrolment, clinical examination,anthropometric measurement and a questionnaire will be administered to each participant at baseline and patients will be followed up every six months. Our tests and examinations include: blood/urine sample and biochemical measurements, office blood pressure recording, carotid ultrasonograph, echocardiograph, pulse wave velocity, pulse wave analysis, 4-limb blood pressure recording, body mass index, etc. Baseline measurement will also include the assessments on target organ damages(TODs) and the conventional CV risk factors. In the follow-up, the incidence of CV events and mortality will be recorded. The Northern Shanghai Risk Score will be calculated, with considerations on CV risk factors and TODs.

Study Design

Study Type:
Observational [Patient Registry]
Actual Enrollment :
1920 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Epidemic Profile of Left Ventricular Diastoic Dysfunction in the Community Elderly and Establishing Prediction Model: the Northern Shanghai Study
Actual Study Start Date :
Jul 10, 2014
Actual Primary Completion Date :
Jul 10, 2014
Actual Study Completion Date :
Aug 10, 2014

Arms and Interventions

Arm Intervention/Treatment
Left Ventricular Diastoic Dysfunction Classification

normal diastole pattern:E/A>1,DT 160~220 ms,S/D >1,AR 0.22-0.32m/sec,E/e'< 8 diastolic dysfunction pattern Impaired relaxation pattern:E/A< 1,DT > 220 ms,S/D > 1,AR 0.21-0.28 m/sec,E/e'<10 Pseudo-normalization pattern:E/A> 1,DT 150~210 ms,S/D < 1,AR ≥0.35m/sec,E/e'≥ 10 Restrictive pattern:E/A ≥ 2,DT < 150 ms,S/D <1,AR ≥0.25m/sec,E/e'≥10

Other: Diuretic,Betaloc,antiplatelet drugs
According to international guidelines,we treated patinets who suffered from different disease

Outcome Measures

Primary Outcome Measures

  1. left ventricular diastolic dysfunction [From July 2014 to August 2019]

    All the ultrasonography measurements are performed with a MyLab 30 CV machine (ESAOTE SpA, Genoa, Italy), according to the American Society of Echocardiography (ASE) recommendations.The echocardiography is performed in the left decubitus position. Left ventricular (LV) internal diameter at end-diastole (LVIDd) and septal (SWTd) and posterior wall thickness at end-diastole (PWTd) are measured directly. left ventricular diastolic dysfunction including: Impaired relaxation pattern:E/A< 1,DT > 220 ms,S/D > 1,AR 0.21-0.28 m/sec,E/e'<10 Pseudo-normalization pattern:E/A> 1,DT 150~210 ms,S/D < 1,AR ≥0.35m/sec,E/e'≥ 10 Restrictive pattern:E/A ≥ 2,DT < 150 ms,S/D <1,AR ≥0.25m/sec,E/e'≥10

Eligibility Criteria

Criteria

Ages Eligible for Study:
55 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. age 55 years or more

  2. informed consent should be signed voluntarily

  3. local residents from communities in northern Shanghai and available for long-term follow-up

Exclusion Criteria:
  1. was diagnosed with serious heart disease (NYHA≥IV) or end-stage renal disease (CKD ≥4 stage)

  2. suffered from cancer or his/her life expectancy is <5 years

  3. had stroke within 3 months

  4. is not willing to participate in the clinical study

  5. has to quit the trial due to other diseases

  6. violates the protocol or loses contact with the laboratory staff.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Ya-Wei Xu

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ya-Wei Xu, Shanghai 10th People's Hospital, Shanghai 10th People's Hospital
ClinicalTrials.gov Identifier:
NCT03735251
Other Study ID Numbers:
  • ELITISM
First Posted:
Nov 8, 2018
Last Update Posted:
Apr 26, 2021
Last Verified:
Jul 1, 2014
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ya-Wei Xu, Shanghai 10th People's Hospital, Shanghai 10th People's Hospital
Additional relevant MeSH terms:

Study Results

No Results Posted as of Apr 26, 2021